NRO-CMK
Neurodegenerative (Normal-Tension) Glaucoma
PreclinicalActive
Key Facts
About Neuroptika
Neuroptika is a private, preclinical biotech developing innovative treatments for retinal diseases, primarily glaucoma and age-related macular degeneration (AMD). The company's pipeline includes two lead programs: NRO-CMK, a neuroprotective gene therapy for glaucoma targeting retinal ganglion cells, and NRO-VTN, an antibody-based therapy aimed at inhibiting drusen formation in dry AMD. Founded in 2019 and led by a co-CEO team with expertise in science/IP and corporate finance, the company is positioned to address the growing global patient population with significant unmet medical needs. Neuroptika is currently in the preclinical research and development phase.
View full company profile